. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Invest New Drugs. 2018 Jun 22;37(2):238–251. doi: 10.1007/s10637-018-0622-9

Table 2.

Composition of benzo(a)pyrene-DNA adducts (pmol/μg DNA) in colon and liver of Apc^Min male mice treated with resveratrol (RVT) and benzo(a)pyrene (BaP; alone and in the presence of RVT).

Organ/Adduct type	BaP	RVT prior to BaP	BaP + RVT
Colon
Deoxyadenosine adduct (dA)	820 ± 80	710± 77	446± 40*
Deoxyguanosine adduct (dG)	3640 ± 325	3525 ±335	2252 ± 212*
Deoxycytidine adduct (dC)	240 ± 25	192±18	85 ± 8*
Deoxythymidine adduct (dT)	100 ± 12	84 ± 9	28 ± 2*
Liver
Deoxyadenosine adduct (dA)	358 ± 17	244 ± 12	154± 3.5*
Deoxyguanosine adduct (dG)	1202 ± 34	1158 ± 24	882± 21*
Deoxycytidine adduct (dC)	32 ± 1.2	21 ± 1.0	18 ± 0.8*
Deoxythymidine adduct (dT)	9 ± 0.45	5 ± 0.35	4 ± 0.2*

Values represent mean ± standard error (n = 10). Asterisks denote statistical significance (p < 0.05) of respective adduct types for BaP and RVT administered together compared to BaP alone administration.